214 related articles for article (PubMed ID: 9125599)
1. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
Sevin BU; Perras JP
Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
3. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
4. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
6. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
7. Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
Gerhardt RT; Perras JP; Sevin BU; Petru E; Ramos R; Guerra L; Averette HE
Am J Obstet Gynecol; 1991 Aug; 165(2):245-55. PubMed ID: 1872324
[TBL] [Abstract][Full Text] [Related]
8. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
Untch M; Sevin BU; Perras JP; Angioli R; Baibl A; Nguyen HN; Hightower RD; Averette HE
Gynecol Oncol; 1992 Nov; 47(2):172-8. PubMed ID: 1468695
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines.
Gibb RK; Taylor DD; Wan T; O'Connor DM; Doering DL; Gerçel-Taylor C
Gynecol Oncol; 1997 Apr; 65(1):13-22. PubMed ID: 9103385
[TBL] [Abstract][Full Text] [Related]
13. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
14. Study on the sensitivity of primary tumor cells of patients with cervical cancer to chemotherapeutic combinations.
Qiu F; Zhao X
J BUON; 2018; 23(1):117-123. PubMed ID: 29552770
[TBL] [Abstract][Full Text] [Related]
15. The use of ATP bioluminescence assays in selecting a drug screen panel for chemosensitivity testing of uterine cancer cell lines.
Nguyen HN; Sevin BU; Averette HE; Perras J; Donato D; Penalver M
Gynecol Oncol; 1992 May; 45(2):185-91. PubMed ID: 1592285
[TBL] [Abstract][Full Text] [Related]
16. In vitro testing of platinum-based drugs on a panel of human ovarian tumour cell lines.
Garner CM; Hubbold LM; Chakraborti PR
Br J Biomed Sci; 2002; 59(1):15-9. PubMed ID: 12000179
[TBL] [Abstract][Full Text] [Related]
17. Extreme drug resistance assay results do not influence survival in women with epithelial ovarian cancer.
Karam AK; Chiang JW; Fung E; Nossov V; Karlan BY
Gynecol Oncol; 2009 Aug; 114(2):246-52. PubMed ID: 19500821
[TBL] [Abstract][Full Text] [Related]
18. Effect of melatonin and pineal extracts on human ovarian and mammary tumor cells in a chemosensitivity assay.
Bartsch H; Buchberger A; Franz H; Bartsch C; Maidonis I; Mecke D; Bayer E
Life Sci; 2000 Nov; 67(24):2953-60. PubMed ID: 11133007
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
20. In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms.
Koechli OR; Schaer GN; Sevin BU; Perras JP; Schenk V; Rodriguez M; Untch M; Steren A; Haller U
Anticancer Drugs; 1995 Feb; 6(1):94-100. PubMed ID: 7756689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
